CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 145 filers reported holding CYMABAY THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is 0.76 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,307 | +215.4% | 423 | -4.3% | 0.00% | – |
| Q1 2022 | $2,000 | 0.0% | 442 | 0.0% | 0.00% | – |
| Q4 2021 | $2,000 | 0.0% | 442 | 0.0% | 0.00% | – |
| Q3 2021 | $2,000 | 0.0% | 442 | 0.0% | 0.00% | – |
| Q2 2021 | $2,000 | 0.0% | 442 | 0.0% | 0.00% | – |
| Q1 2021 | $2,000 | 0.0% | 442 | 0.0% | 0.00% | – |
| Q4 2020 | $2,000 | -50.0% | 442 | 0.0% | 0.00% | – |
| Q3 2020 | $4,000 | +100.0% | 442 | 0.0% | 0.00% | – |
| Q2 2020 | $2,000 | – | 442 | 0.0% | 0.00% | – |
| Q1 2020 | $0 | -100.0% | 442 | -21.6% | 0.00% | – |
| Q4 2019 | $2,000 | – | 564 | +1466.7% | 0.00% | – |
| Q3 2019 | $0 | -100.0% | 36 | -99.6% | 0.00% | – |
| Q1 2019 | $136,000 | +30.8% | 10,260 | -21.8% | 0.00% | – |
| Q4 2018 | $104,000 | -11.9% | 13,120 | +23.1% | 0.00% | – |
| Q3 2018 | $118,000 | -22.4% | 10,660 | -6.2% | 0.00% | – |
| Q2 2018 | $152,000 | – | 11,360 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 2,254,502 | $20,741,000 | 14.54% |
| Versant Venture Management, LLC | 1,048,601 | $9,647,127,000 | 10.15% |
| Abingworth LLP | 1,147,077 | $10,553,000 | 7.65% |
| Omega Fund Management, LLC | 551,477 | $5,074,000 | 3.67% |
| Opaleye Management Inc. | 665,000 | $6,118,000 | 1.96% |
| DAFNA Capital Management LLC | 361,164 | $3,323,000 | 1.79% |
| Boxer Capital, LLC | 1,012,986 | $9,319,000 | 1.70% |
| Foresite Capital Management III, LLC | 600,000 | $5,520,000 | 1.55% |
| NEXTHERA CAPITAL LP | 536,568 | $4,936,000 | 0.91% |
| Perceptive Advisors | 2,685,882 | $24,710,000 | 0.82% |